Multidisciplinary

Top Medical News
Brensocatib has no impact on COVID-19 clinical outcomes
Roshini Claire Anthony, an hour ago

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

PPIs reduce upper GI bleeding in patients on anticoagulants
an hour ago
Use of proton pump inhibitors (PPIs) helps prevent upper gastrointestinal (GI) bleeding in patients using oral anticoagulants, reveals a study.
Younger patients with small lesions unlikely to see nAMD recurrence
2 hours ago
In neovascular age-related macular degeneration (nAMD), the absence of exudative recurrence after three loading doses of antivascular endothelial growth factor (VEGF) is associated with younger age, smaller lesion size, and having no fibrovascular pigment epithelial detachment (PED), a recent study has found.
Treatment-resistant depression imposes high healthcare utilization
3 hours ago
Patients suffering from treatment-resistant depression (TRD) have higher healthcare resource utilization (HRU) associated with psychiatric services, reports a recent study.
Plantar heel pain hurts health-related quality of life
5 hours ago
People suffering from plantar heel pain (PHP) have worse generic and foot-specific health-related quality of life (HRQoL), a recent study has found.
Pemafibrate superior to conventional fibrates in T2DM
17 hours ago
Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.
Home-based tDCS a safe, feasible poststroke rehabilitation modality
21 hours ago
Remotely supervised transcranial direct current stimulation (tDCS) helps improve cognitive function in stroke survivors, especially those with moderate cognitive decline, according to a study from Korea.
Special Reports
Bone Pain in Multiple Myeloma: Timely Referral Key to Better Outcomes
01 Oct 2022
Multiple myeloma (MM) is an uncommon cancer usually afflicting those in their 70s. About 85% of these patients present with bone pain. When presenting to an orthopaedic surgeon, patients usually complain about back pain or bone pain. To differentiate between MM and regular bone pain, three criteria are looked at: the characteristic of the pain—MM-associated pain is persistent even with rest and can sometimes disturb sleep; the site of the pain—usually very generalized and covers entire back; and the patient’s general outlook—MM patients can look extremely unwell and complain of lethargy, loss of appetite, weight loss, and complain of feeling unwell in general.
Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 01 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
My Early Experience of Systane® COMPLETE Programme
01 Oct 2022
A study on Systane® COMPLETE was conducted from March to April 2020. Twenty-six patients were enrolled at the beginning of the study, but only 21 patients completed the study at 1-month follow-up. The data was analysed only for those who completed the 4-week review during the study period. Systane® COMPLETE was initiated at four to six times per day, instilled into both eyes as a single therapy for dry eyes
Product Highlight - Idacio
13 Sep 2022
Adalimumab soln for inj 40 mg/0.8 mL
Product Highlight - Ravida
13 Sep 2022
Ravidasvir 200 mg tab
Product Highlight - Talzenna
13 Sep 2022
Talazoparib 0.25 mg hard cap
The successful treatment of
selected deleterious genetic
diseases using gene therapies
01 Sep 2022
Patients with rare genetic diseases usually have limited treatment options if any is available. Gene therapy has been progressing tremendously especially in the treatment of challenging rare genetic diseases such as spinal muscularatrophy (SMA). Modification of genetic diseases perhaps to the point of cure may be possible with gene therapy. Two renowned experts in clinical genetics discuss gene therapies for selected deleterious genetic diseases
Conference Reports
Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 01 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Renal denervation bounces back in 3-year follow-up study
Audrey Abella, 29 Sep 2022
Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).
Antihypertensive dosing TIME does not affect CV outcomes
Roshini Claire Anthony, 26 Sep 2022

Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.

SVS endobronchial valve improves QoL in patients with emphysema
Audrey Abella, 26 Sep 2022
In the 24-month follow-up results of the EMPROVE trial, treatment with the Spiration Valve System (SVS) endobronchial valve provided a sustained clinically significant benefit in disease-specific health-related quality of life (QoL) in patients with severe heterogeneous emphysema.
Does frozen embryo transfer up hypertension risk during pregnancy?
Roshini Claire Anthony, 25 Sep 2022

The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.

P2Y12 monotherapy wins against aspirin for secondary prevention of CAD
Elaine Soliven, 24 Sep 2022
Compared with aspirin alone, treatment with a P2Y12 inhibitor (clopidogrel or ticagrelor) is associated with lower risks of cardiovascular (CV) death, myocardial infarction (MI), or stroke in patients with established coronary artery disease (CAD), according to the PANTHER* trial presented at ESC 2022.
Rocatinlimab a new treatment option for head and neck AD?
Audrey Abella, 23 Sep 2022
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.